Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00012259 | Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia | PHASE2 | COMPLETED | 31 | — | — | Dec 11, 2000 | Mar 27, 2002 | Jun 10, 2021 | 20 | United States, Canada |
Conventional Response Rate defined as the achievement of complete hematologic remission (CHR), partial hematologic remission (PHR), hematologic improvement (HI), partial response (PR), or back to chronic phase (BCP).
| Arm | Type | Description |
|---|---|---|
| troxacitabine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| troxacitabine | DRUG | - |
DISEASE CHARACTERISTICS: Diagnosis of Philadelphia chromosome-positive blastic phase chronic myelogenous leukemia (CML) with blasts of non-lymphoid origin Blastic phase defined as: At least 30% blasts in the blood or bone marrow OR Presence of extramedullary infiltration outside the liver or spleen ...